Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.93 USD | +2.24% | +25.11% | +32.96% |
Financials (USD)
Sales 2024 * | 68.34M | Sales 2025 * | 84.72M | Capitalization | 918M |
---|---|---|---|---|---|
Net income 2024 * | -101M | Net income 2025 * | -108M | EV / Sales 2024 * | 13.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.8 x |
P/E ratio 2024 * |
-6.8
x | P/E ratio 2025 * |
-6.9
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.08% |
Latest transcript on Ocular Therapeutix, Inc.
1 day | +2.24% | ||
1 week | +25.11% | ||
Current month | +25.11% | ||
1 month | -29.74% | ||
3 months | +18.60% | ||
6 months | +108.80% | ||
Current year | +32.96% |
Managers | Title | Age | Since |
---|---|---|---|
Donald Notman
DFI | Director of Finance/CFO | 64 | 17-09-24 |
Chief Tech/Sci/R&D Officer | - | 21-09-27 | |
Rabia Ozden
CTO | Chief Tech/Sci/R&D Officer | 56 | 21-01-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Adrienne Graves
BRD | Director/Board Member | 69 | 23-07-09 |
Director/Board Member | 76 | 12-11-04 | |
Merilee Raines
BRD | Director/Board Member | 68 | 21-09-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +8.42% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 5.93 | +2.24% | 2,436,694 |
24-05-06 | 5.8 | -6.00% | 5,676,152 |
24-05-03 | 6.17 | +5.11% | 4,643,067 |
24-05-02 | 5.87 | +16.93% | 3,479,674 |
24-05-01 | 5.02 | +5.91% | 3,033,532 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.96% | 897M | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- OCUL Stock